Orchid Pharma Limited (ORCHPHARMA) has announced its strategic expansion into Latin America through a licensing and supply agreement with Laboratorio Libra S.A. (Libra). This partnership will cover the commercialization of Exblifep® (cefepime/enmetazobactam) across nine Latin American markets, including Chile, Costa Rica, Ecuador, El Salvador, Guatemala, Honduras, Panama, Paraguay, and Uruguay. Exblifep is a novel antibiotic combination indicated for complicated urinary tract infections and hospital-acquired and ventilator-associated bacterial pneumonia caused by Gram-negative pathogens.

Strategic Partnership

Libra receives exclusive rights to register, import, and market Exblifep in these countries, while Orchid Pharma manufactures and supplies the finished dosage form. The collaboration aims to provide clinicians in the region with a new option for treating serious Gram-negative hospital infections, addressing the growing challenge of antimicrobial resistance.

Market Potential

Over the first 10 years, the partnership is expected to represent a potential commercial opportunity of approximately USD 80 million, based on projected demand across these markets. The agreement underscores Orchid Pharma’s commitment to expanding its footprint in the Latin American pharmaceutical market, leveraging Libra’s established presence and expertise in the region.

Manish Dhanuka, Managing Director of Orchid Pharma Limited, stated, ‘Extending Exblifep into Latin America is a priority for Orchid, and Libra is well placed to lead its introduction across these markets. Together, we aim to give clinicians in the region a new option for treating serious Gram-negative hospital infections.’ Carlos Scherschener, CEO of Laboratorio Libra S.A., added, ‘We are honored to partner with Orchid Pharma to bring Exblifep to Latin America, expanding access to an innovative therapeutic option for patients across the region while contributing to the response to the growing challenge of antimicrobial resistance.’

This expansion marks a significant milestone for Orchid Pharma as it continues to innovate and expand its global footprint in the pharmaceutical industry.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Orchid Pharma Limited

Orchid Pharma Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Orchid falls 12.5% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. No meaningful dividend — total return is entirely dependent on capital appreciation. The stock holds at 65% of its 52-week range with RSI at 36. In other words, neither side has a clear edge right now. The stock rises -12.5% in three months on 22.3% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Orchid Pharma Limited.

Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA) announced today that it will present updated long-term efficacy and safety results from the locally advanced cutaneous squamous cell carcinoma (laCSCC) and metastatic CSCC (mCSCC) expansion cohorts from the pivotal CK-301-101 trial of UNLOXCYT® (cosibelimab-ipdl) at the European Society for Medical Oncology (ESMO) Congress on October 24, 2026 in Madrid, Spain.

Key Findings from ESMO 2026 Presentation

The ESMO abstract expands the pivotal analysis to 205 patients across three advanced CSCC cohorts using centrally-reviewed data. Notably, 34% of patients with locally advanced disease achieved a complete response (CR), while 17%-21% of metastatic patients achieved a CR. The tolerability profile remained consistent with earlier analyses, with a low level of high-grade immune-related adverse events (irAEs).

Clinical Implications

These results underscore the potential for cosibelimab to deliver clinically meaningful and durable benefit for patients with advanced CSCC. The consistent benefit-risk profile over time, with maintained response rates and increasing proportion of complete responses, highlights the promising efficacy of UNLOXCYT® in treating advanced skin cancers.

Ahmad Naim, MD, Senior Vice President, North American Chief Medical Officer, Sun Pharma, emphasized, ‘These findings of improvements in clinical response and consistent safety profile of low irAEs over time support the unmet need for patients with advanced CSCC. And reflects Sun Pharma’s continued commitment to advancing care and providing innovative treatment options that address the needs of patients with difficult-to-treat skin cancers.’

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Sun falls 9.0% over three months and has not found a floor yet. The PEG reaches 3.29. The stock trades on brand and index weight, not on growth. Premium net margins of 20.2% demonstrate strong cost discipline and a wide competitive moat. The stock holds at 38% of its 52-week range with RSI at 37. In other words, neither side has a clear edge right now. Revenue grows at 10.4% and profits at 10.6% CAGR, with D/E of 0.03. Meanwhile, the stock dips 9.0% in three months without any fundamental deterioration. Consequently, the stock quietly becomes cheaper relative to earnings power. For long-term investors, that is a feature. Check Fundamentals of Sun Pharmaceutical Industries Limited.

Dr. Reddy’s Laboratories Limited (DRREDDY) showcased robust financial performance for Q2FY27, as per consolidated financial statements under IFRS. The company reported a revenue of ₹8,671 Cr, marking a 1.5% year-on-year growth. The EBITDA margin stood at 20.6%, reflecting consistent double-digit base business growth. The company’s progress across strategic priorities highlights its commitment to innovation and market expansion.

Financial Highlights

The financial highlights for Q2FY27 include a reported EBITDA of ₹1,783 Cr, a 24% year-on-year increase. The PBT reached ₹1,228 Cr, up 33% YoY, and PAT stood at ₹925 Cr, with a 36% YoY growth. Notably, the RoCE was annualized at 9.5%, and the net cash surplus stood at ₹2,502 Cr.

Strategic Initiatives

Dr. Reddy’s Laboratories Limited has made significant strides in its strategic initiatives. The company partnered with Takeda for India’s first CDSCO approved dengue vaccine, QDENGA, set to launch in private markets in H1 2027. Additionally, collaborations with Gilead Sciences and GARDP Foundation have expanded its global footprint.

The company also secured approval for rituximab biosimilar from the USFDA and launched nivolumab biosimilar in India. Furthermore, generic semaglutide has been approved in 10 countries across Latin America, Africa & the Middle East, as well as Canada & India.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Dr. Reddy’s Laboratories Limited

Dr. Reddy’s Laboratories Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Dr. moves sideways over three months, with neither buyers nor sellers taking control. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. Revenue contracts at 11.0% CAGR. That signals structural headwinds, not a short-term blip. The stock holds at 42% of its 52-week range with RSI at 58. In other words, neither side has a clear edge right now. Revenue grows at 11.0% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Dr. Reddy’s Laboratories Limited.